The global respiratory syncytial virus (RSV) diagnostics market size reached US$ 920 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,568 Million by 2028 exhibiting a growth rate (CAGR) of 9.3% during 2022-2028.

Respiratory syncytial virus (RSV) is a viral infection of the lungs and respiratory tract, which can cause asthma, hospitalization, pneumonia, repeated infections, middle ear infection, and death. It can be diagnosed using blood tests, chest x-rays, a swab of secretions, and pulse oximetry by checking for signs like lung inflammation, white blood cell (WBC) count, and oxygen levels in the blood. Some of the commonly available treatment options for RSV are over-the-counter (OTC) medications, intravenous (IV) fluids, humidified oxygen, mechanical ventilation, and inhaled bronchodilators.

Respiratory Syncytial Virus (RSV) Diagnostics Market Trends:
RSV infection can be more serious during the neonatal period as children under two years of age tend to develop severe respiratory symptoms. This, in confluence with the rising focus of parents on child medical care, represents one of the crucial factors fostering the growth of the market. Moreover, the high survival rates after early diagnosis and the easy availability of diagnostic modalities act as other growth-inducing factors. Apart from this, the improving healthcare infrastructure and favorable reimbursement policies for the treatment of hospitalized infants are also contributing to market growth. Furthermore, the advent of advanced techniques like bio- and nanotechnology is facilitating the development of modern detection systems for RSV, such as western blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). Besides this, governing agencies of numerous countries are funding research and development (R&D) projects for the development of new therapeutics. Other factors projected to drive the market are the growing number of clinical vaccine trials, the escalating demand for in-vitro diagnostics, rising incidences of childhood pneumonia and the increasing adoption of molecular diagnostics.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global respiratory syncytial virus (RSV) diagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product and end use.

Breakup by Product:

Direct Fluorescent Antibody (DFA) Method
Rapid Antigen Diagnostic Test (RADTs)
Molecular Diagnostics
Chromatographic Immunoassay
Diagnostic Imaging
Gel Microdroplets
Flow Cytometry
Others

Breakup by End Use:

Hospitals and Clinics
Laboratory
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioM?rieux SA, Bio-Rad Laboratories Inc., Coris BioConcept, DiaSorin Molecular LLC (DiaSorin Inc), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics Incorporated, Quidel Corporation and Thermo Fisher Scientific Inc.

Key questions answered in this report:
How has the global respiratory syncytial virus (RSV) diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global respiratory syncytial virus (RSV) diagnostics market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global respiratory syncytial virus (RSV) diagnostics market and who are the key players?
What is the degree of competition in the industry?